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Purpose: To examine the potential of NIH-maintained human embryonic stem cell (hESC) lines TE03 and UC06 to
differentiate into retinal progenitor cells (hESC-RPCs) using the noggin/Dkk-1/IGF-1/FGF9 protocol. An additional goal
is to examine the in vivo dynamics of maturation and retinal integration of subretinal and epiretinal (vitreous space) hESC-
RPC grafts without immunosuppression.
Methods: hESCs were neuralized in vitro with noggin for 2 weeks and expanded to derive neuroepithelial cells (hESC-
neural precursors, NPs). Wnt (Integration 1 and wingless) blocking morphogens Dickkopf-1 (Dkk-1) and Insulin-like
growth factor 1 (IGF-1) were used to direct NPs to a rostral neural fate, and fibroblast growth factor 9 (FGF9)/fibroblast
growth factor-basic (bFGF) were added to bias the differentiation of developing anterior neuroectoderm cells to neural
retina (NR) rather than retinal pigment epithelium (RPE). Cells were dissociated and grafted into the subretinal and
epiretinal space of young adult (4–6-week-old) mice (C57BL/6J x129/Sv mixed background). Remaining cells were
replated for (i) immunocytochemical analysis and (ii) used for quantitative reverse transcription polymerase chain reaction
(qRT–PCR) analysis. Mice were sacrificed 3 weeks or 3 months after grafting, and the grafts were examined by histology
and immunohistochemistry for survival of hESC-RPCs, presence of mature neuronal and retinal markers, and the dynamics
of in vivo maturation and integration into the host retina.
Results: At the time of grafting, hESC-RPCs exhibited immature neural/neuronal immunophenotypes represented by
nestin and neuronal class III β-tubulin, with about half of the cells positive for cell proliferation marker Kiel University -
raised antibody number 67 (Ki67), and no recoverin-positive (recoverin [+]) cells. The grafted cells expressed eye field
markers paired box 6 (PAX6), retina and anterior neural fold homeobox (RAX), sine oculis homeobox homolog 6 (SIX6),
LIM homeobox 2 (LHX2), early NR markers (Ceh-10 homeodomain containing homolog [CHX10], achaete-scute complex
homolog 1 [MASH1], mouse atonal homolog 5 [MATH5], neurogenic differentiation 1 [NEUROD1]), and some retinal
cell  fate  markers  (brain-specific  homeobox/POU  domain  transcription  factor  3B  [BRN3B],  prospero  homeobox  1
[PROX1], and recoverin). The cells in the subretinal grafts matured to predominantly recoverin [+] phenotype by 3 months
and survived in a xenogenic environment without immunosuppression as long as the blood–retinal barrier was not breached
by the transplantation procedure. The epiretinal grafts survived but did not express markers of mature retinal cells. Retinal
integration into the retinal ganglion cell (RGC) layer and the inner nuclear layer (INL) was efficient from the epiretinal
but not subretinal grafts. The subretinal grafts showed limited ability to structurally integrate into the host retina and only
in cases when NR was damaged during grafting. Only limited synaptogenesis and no tumorigenicity was observed in
grafts.
Conclusions: Our studies show that (i) immunosuppression is not mandatory to xenogenic graft survival in the retina, (ii)
the subretinal but not the epiretinal niche can promote maturation of hESC-RPCs to photoreceptors, and (iii) the hESC-
RPCs from epiretinal but not subretinal grafts can efficiently integrate into the RGC layer and INL. The latter could be
of value for long-lasting neuroprotection of retina in some degenerative conditions and glaucoma. Overall, our results
provide new insights into the technical aspects associated with cell-based therapy in the retina.
Photoreceptor death in retinal and macular degenerative
diseases  is  a  leading  cause  of  inherited  vision  loss  in
developed  countries.  Novel  therapeutic  strategies  have
recently emerged, from mechanical to cell based, to repair
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neural circuits affected by photoreceptor (PR) cell loss [1].
Trophic factor delivery to extend the life of dying PRs has
been  pursued  in  experimental  animals  [2-5]  and  in  some
instances in the clinic [6]. Gene therapy approaches have been
applied  successfully  in  one  type  of  Leber  congenital
amaurosis  and  remain  viable  when  etiology  of  disease  is
understood  and  the  size  of  a  gene  is  not  prohibitive  for
packaging capacity of the viral vector. Retinal implants [7,8]
utilize a high-tech mechanical device placed on the retina to
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920capture photons and transmit the electric signals to ganglion
cells. Such a device is designed to replace lost PRs and has
been used in the clinic with promising outcomes [9,10]. The
concept of transplanting an immature retinal sheet into the
subretinal space goes back to 1946 [11]. While seemingly
unattainable,  the  approach  has  shown  some  promising
outcomes [12], with the ability of such grafts to survive long-
term, preserve layers, establish synaptic connectivity in the
host retina, and evoke activity in the visual cortex [13,14].
Transplantation of human embryonic stem cell (hESC)-
or  induced  pluripotent  stem  cell  (iPS)-derived  retinal
progenitors or retinal neurons is a relatively recent direction
for retinal therapies [15]. hESCs or iPSs can be directed to
retinal fate with variable efficiency [16-21]. Compared to the
retinal sheet transplantation strategy where the donor retina
and its preservation constitute major limitations, the stem cell
approach is based on using hESCs or iPSs, which provide an
unlimited  source  of  cells.  Furthermore,  there  is  optimism
stemming from research on mouse ESCs that such human
protocols might be improved by engineering the development
of the whole retina in a dish [22].
The transplantation of retinal cells into mammalian retina
produces  variable  outcomes  and  success.  A  greater
understanding of biology and improvements in methodology
are required before such protocols may be introduced into the
clinic [19,23-27]. Some of the key obstacles in transplantation
studies include immunological compatibility of graft and host
[27,28], the outer limiting membrane (OLM) being a barrier
for retinal integration [25,26,29], and glial cells/glial scar at
transplantation site preventing efficient integration [19,26,
30,31]. The retinal stem cell-based approach requires that
transplanted cells migrate into the retinal layer(s) affected by
genetic  lesion,  undergo  terminal  maturation,  acquire  the
appropriate  cell  fate,  and  establish  needed  synaptic
interactions. This is different from other systems, such as
transplantation of insulin-producing β-cells [32], skin cells
[33], or blood cells [34], which require the newly grafted cells
to primarily acquire the proper postmitotic cell fate. Although
biology  of  specific  synaptic  connectivity  during  retinal
development  is  still  poorly  understood,  promising  reports
indicate the feasibility of this direction, and such an approach,
still largely heuristic in nature, may at least partially alleviate
blindness  in  experimental  animals  with  PR  degeneration
[29,35-37]. The progress in cell-sorting techniques [38,39]
based on cell-surface antigens rather than fluorescent markers
gives further hope of generating a defined cell population for
cell replacement.
Transplantation  is  traditionally  accompanied  by
immunosuppression, which has detrimental side effects, such
as tumorigenesis [40,41], and may contribute to regenerative
processes in the central nervous system (CNS) [42,43], thus
masking the therapeutic effect exerted by neural graft. The
retina and brain are reported to be partially immunoprivileged
sites  [31,44,45].  However,  survival  of  neural  grafts  in
subretinal space with and without immunosuppression still
varies [5,27,46-50], requiring a more systematic examination.
Interestingly, the transplanted neural progenitors themselves
may exert an immunomodulatory effect on the host CNS
[51].  Allogeneic  mouse  retinal  grafts  can  also  undergo
apoptosis in degenerating mouse retina [24].
This  study  was  initiated  to  examine  the  survival  and
integration  of  hESC-derived  neural  progenitors  that  were
transplanted into normal adult mouse retina with no immune
suppression.  We  show  that  xenogenic  human  grafts
comprising of postmitotic hESC-RPCs carrying PR markers
can survive in adult mammalian retina for up to 12 weeks with
no signs of deterioration. We also report that hESC-RPCs can
integrate from the epiretinal grafts into host’s RGC layer and
inner nuclear layer (INL) but not PR layer. The cells from the
subretinal grafts, however, show limited integration into the
PR  layer  and  only  when  retina  was  damaged  during
transplantation.  We  also  noted  the  instructing  role  of  the
subretinal  but  not  epiretinal  niche  in  promoting  further
maturation of grafted cells to PRs. Taken together, our data
may help in refining protocols of hESC-derived retinal cell
transplantation.
METHODS
Animals: Young adult C57BL/6Jx129/SvJ wild-type mice (4–
6-weeks old; the Jackson Laboratory, Bar Harbor, Maine)
were used for transplantation experiments. All animals were
housed and treated in accordance with the ARVO Statement
for the Use of Animals in Ophthalmic and Vision Research
and in accordance with the standards issued by the NIH animal
facilities, NIH approval #ASP 08–610.
Human embryonic stem cells: hESCs were maintained and
supplied by the NIH Stem Cell Unit. TE03 (Technion-Israel
Institute of Technology, Haifa, Israel) and UC06 (University
of  California  San  Francisco,  San  Francisco,  CA)  were
separately differentiated and used for grafting.
Cell  culturing  and  differentiation  factors:  Neurobasal
medium with B27/N2 supplementation (all from Invitrogen,
Grand Island, NY) and plastic Petri dishes (Corning Inc.,
Corning, NY) covered with 0.1% gelatin (Sigma-Aldrich, St.
Louis, MO) were used for cell culture during differentiation.
Noggin,  Dkk-1,  IGF-1,  FGF9  were  from  R&D  Systems,
Minneapolis, MN, and bFGF was from Sigma-Aldrich, St.
Louis, MO.
Cryosectioning  and  slides:  The  Microm  HM550  cryostat
(Thermo Scientific, Rockville, MD) was used to produce 16-
μm serial sections of mouse eyes. Microscope slides were
purchased  from  Fisher  Scientific  (Pittsburg,  PA).  Glass
coverslips were purchased from Brain Research Laboratories
(Newton, MA).
In vitro differentiation: hESC lines were grown on a mouse
embryonic fibroblast feeder layer (CF1 strain, The Jackson
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described  (NIH  research).  The  colonies  (day  4–5  after
passage) were dislodged and placed on gelatin-coated Petri
dishes and cultured at high density in Neurobasal medium
supplemented with 1x B27 without retinoic acid, 1x N2, 1x
penicillin–streptomycin  antibiotic  mix,  L-glutamine  (1%),
Minimal Essential Medium nonessential amino acid solution
(1%;  all  from  Invitrogen),  BSA  fraction  V  (0.1%),  β-
mercaptoethanol (0.1 mM; both from Sigma-Aldrich), and
recombinant noggin (100 ng/ml; R&D Systems) but without
bFGF  to  induce  neuralization  [18].  At  14  days  of
differentiation, the cultures were supplemented with bFGF
(10 ng/ml) [19], and 50% of the media was renewed every
other  day.  At  day  28,  neural  rosettes  were  excised
mechanically and replated as large clusters of neuroepithelial
cells (hESC-NPs) [6] on gelatin/laminin-coated plates and
cultured  at  high  density  (95%–100%  confluency).  Wnt-
blocking morphogens Dkk-1 and IGF-1 (10 ng/ml each) were
applied for 1 week immediately after replating to anteriorize
cells to a rostral neural fate [12]. Cells were then cultured
further with the addition of FGF9 and bFGF (both at 10 ng/
ml) as well as noggin until grafting to bias cells to an NR rather
than an RPE cell fate [13-15]. At day 50, hESC-RPCs were
dissociated  with  cell  dissociation  buffer  (Invitrogen)  and
trypsin-like  enzyme  (Invitrogen)  and  suspended  in
Neurobasal medium at ~50×103 cells/μl for transplantation.
Immunocytochemical and quantitative reverse transcription
coupled  polymerase  chain  reaction  analysis  of  cells:
Immediately after transplantation, some of the remaining cells
were replated to evaluate the viability and differentiated state
of transplanted cells. Antibodies against human nuclei (HNu),
human  nestin,  recoverin,  Kiel  University-raised  antibody
number 67 (Ki67), doublecortin (DCX), and neuronal class
III  β-tubulin  (Tuj1)  were  used  for  this  analysis.
Immunohistochemistry was done as described previously [6].
Total RNA was prepared from (i) undifferentiated hESC cells
and (ii) cells at day 50 (transplantation) using RNeasy Mini
kit (Qiagen, Valencia, CA) according to the manufacturer’s
protocol; briefly cells were first lysed and then homogenized,
the lysates were then loaded onto the RNeasy silica Mini spin
columns,  and  after  RNA  was  bound  to  silica  gel,  all
contaminants were washed away, and pure concentrated RNA
was eluted in water. RNA was then converted to cDNA with
Superscript  II  (Invitrogen,  Carlsbad,  CA),  and  used  for
quantitative reverse transcription polymerase chain reaction
(qRT–PCR) analysis on an ABI 7900HT Fast Real-Time PCR
System (Applied Biosystems, Foster City, CA) with SYBR
Green Master Mix (Applied Biosystems). Oligonucleotide
primers (Table 1) specific to (i) pluripotent hESCs (octamer-
binding  transcription  factor  3/4  [OCT3/4],  NANOG,  sex-
determining region Y gene-related high mobility group box 2
[SOX2]), (ii) markers of the anterior neuroectoderm (forkhead
box  protein  G1  [FOXG1],  [SIX3],  sine  oculis  homeobox
homolog 6 (Drosophila) [SIX6], [LHX2), (iii) markers of the
eye  field  (PAX6,  SIX3,  SIX6,  RAX  [RX]),  (iv)  retinal
progenitors  (CHX10,  MASH1,  NEUROD1),  RPE
(microphthalmia-associated transcription factor, MITF), PRs
(recoverin, cone-rod homeobox gene [CRX], neural retina-
specific  leucine  zipper,  [NRL]),  RGCs  (MATH5,  BRN3B,
insulin gene enhancer protein [ISL1]), and horizontal neurons
(PROX1)  were  used  for  qRT–PCR  analysis,  which  was
performed in triplicate at both time points (“undifferentiated
hESCs” and “day 50, grafting”). The qRT–PCR data were
analyzed using the ΔΔCt method (as described in Livak KJ,
Schmittgen  TD.  Methods  2001  paper),  with  geometric
averaging of β-actin (ACTB) and glyceraldehyde-3-phosphate
dehydrogenase  (GAPDH)  as  the  endogenous  controls
(outlined  in  Vandesompele  J.  et  al.,  Genome  Biol  2002).
Briefly, the standard approach of DNA quantification by real-
time qRT–PCR is based on plotting measured fluorescence
(in our case SYBR Green I cyanine dye incorporated into
DNA during PCR) against the number of PCR cycles on a
logarithmic scale. During the exponential phase of qRT–PCR,
when reagents are not limited, the amount of cDNA (target)
is assumed to be doubling every cycle. First, ΔCt analysis is
done, which takes the Ct (cycle number, or cycle threshold)
value for the gene of interest, divided by Ct of a housekeeping
gene in the same sample, at the point when the signal just
becomes  detectable  above  the  background  and  the
amplification is in exponential phase; the log2 difference is
then generated. The more abundant the mRNA for gene X is,
the quicker this point is reached, thus giving earlier Ct values
and allowing to quantitatively evaluate the expression of gene
X. In our case Ct values were generated automatically using
SDS2.3 software (Life Technologies, Carlsbad, CA). Second,
ΔΔCt analysis is done, where ΔΔCt equals ΔCt [sample] (Ct
value for “day 50” sample normalized to the endogenous
housekeeping  gene)  minus  ΔCt  [reference]  (Ct  value  for
“undifferentiated hESCs also normalized to the endogenous
housekeeping  gene).  Collectively,  ΔΔCt  method  is  a
normalization procedure, which allows comparison of gene
expression levels in different RNA samples by taking into
account the differences in quality and total amount of RNA in
samples. Expression levels at day 50 (grafting) were presented
as log2 values of the expression level differences compared
to that found in undifferentiated hESCs. The analysis was
done in technical triplicates, with one biological replicate.
Subretinal  transplantation:  Transplantation  equipment
included  a  nano-injector  (World  Precision  Instruments,
Sarasota,  FL),  pulled  glass  micropipettes  (Drummond
Scientific  Company,  Broomall,  PA),  29G  insulin  syringe
(Becton  Dickinson  &  CO,  Franklin  Lakes,  NJ),  and  a
dissection microscope (SZ61; Olympus, Center Valley, PA).
General  anesthesia  was  used  during  transplantation  and
included  a  mixture  of  ketamine  (87  mg/kg)  and  xylazine
(10  mg/kg)  administered  intraperitoneally  at  0.1  ml/g
bodyweight. Once properly sedated, the animals were placed
under the dissection microscope; the eyes were covered with
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was made in the cornea using a sharp insulin syringe. Using
the nano-injector, the blunt-ended tip of a micropipette filled
with cells was guided through the incision in the cornea and
advanced trans-retinally until it met resistance due to rigid
choroid/scleral  tissue.  The  needle  was  then  slightly
withdrawn, and as it was very slowly being pulled out to create
space for grafted cells, hESC-RPC suspension (≤1.5 μl, total
of about 50,000 cells) was slowly deposited into the subretinal
space. This transplantation methodology, due to a mouse NR
being  so  thin,  inevitably  left  about  20%  of  grafted  cells
epiretinally,  adjacent  to  the  RGC  layer.  Both  eyes  were
injected  for  each  animal.  For  the  TE03  hESC  line,  26
subretinal grafts (13 animals) were generated; six animals (12
eyes) were analyzed at 3 weeks and seven animals (14 eyes)
were analyzed at 3 months after grafting. For the UC06 hESC
line,  14  subretinal  grafts  (seven  animals)  were  generated;
three animals (six eyes) were analyzed at 3 weeks and four
animals (eight eyes) were analyzed at 3 months after grafting.
Enucleation, fixation, and embedding of eyes for sectioning:
Enucleation  of  the  eye  was  done  with  a  fine-point
microdissection  forceps  and  fine-point  microdissection
scissors (Electron Microscopy Sciences, Ft. Washington, PA).
Eyes were fixed in paraformaldehyde (4%, Sigma-Aldrich)
for 5 min, rinsed with 1x PBS (KD Medical, Columbia, MD;
NaCl 90 g/l; Na2HPO4, anhydrous, 7.10 g/l; KH2PO4, 2.3g/l;
UltraPure  Water),  cryoprotected  in  20%  and  then  30%
TABLE 1. QRT–PCR PRIMERS.
Primers (5′-3′) Gene name
F: AGATGCCTCACACGGAGACT NANOG
R: TTTGCGACACTCTTCTCTGC  
F: TGAGTAGTCCCTTCGCAAGC OCT3/4
R: GCGAGAAGGCAAAATCTGA  
F: GGGGGAATGGACCTTGTATAG SOX2
R: GCAAAGCTCCTACCGTACCA  
F: CCGGAAGACAGGATACAGGT CHX10
R: ACTCCGCCATGACACTGC  
F: TTTGAGTTACAACGGCACCA FOXG1
R: TCTGAGTCAACACGGAGCTG  
F: CCAAGGACTTGAAGCAGCTC LHX2
R: AAGAGGTTGCGCCTGAACT  
F: CAGGTGCCGATGGAAGTC MITF (RPE-SPECIFIC ISOFORM)
R: GCTAAAGTGGTAGAAAGGTACTGCTT  
F: TCACCATGGCAAATAACCTG PAX6
R: CAGCATGCAGGAGTATGAGG  
F: TTCGAGAAGTCCCACTACCC RAX
R: ACTTAGCCCGTCGGTTCTG  
F: CTCCTCCCCCACTCCTTC SIX3
R: GGGTATCCTGATTTCGGTTTG  
F: GGACACTGCAAGCCCAGTAT SIX6
R: ATGATTCGCGCCCTTTCT  
F: CGACTTCACCAACTGGTTCTG MASH1
R: ATGCAGGTTGTGCGATCA  
F: CAGACCTATGGACGCAATCA MATH5
R: CAACCCATTCACAAGATCCA  
F: CCCTTTGAACCCCACCTC BRN3B
R: CTTCCTGCAAACAGCCATCT  
F: CGAGTTGGTACACACCGTCA CRX
R: TCTCTTCACATCTCGCCTTTC  
F: AAGGACAAGAAGCGAAGCAT ISL1
R: TTCCTGTCATCCCCTGGATA  
F: CTGCTCAGGACCTACTAACAACAA NEUROD1
R: GTCCAGCTTGGAGGACCTT  
F: TCCTCTCGGCCATTTCTG NRL
R: CTCAAACTTCATCAAGTCAAAGTCA  
F: AAATATCACCTTATTCGGGAAGTG PROX1
R: TTTTCAAGTGATTGGGTGACA  
F: TAACGGGACCATCAGCAAG RCVRN
R: CCTCGGGAGTGATCATTTTG  
F: GCAACTACGTGGGCGACT TUBB3
R: CGAGGCACGTACTTGTGAGA  
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(Tissue-Tek, Torrance, CA) and serially sectioned at 10 μm.
Histological staining: For cresyl violet (CV) staining, serial
sections were sequentially washed with PBS and deionized
water, stained with CV for about 1 min, dehydrated with
increasing  concentrations  of  ethanol,  mounted  with  DPX
solution  (Sigma-Aldrich),  and  examined  with  a  light
microscope for the presence of hESC-RPC grafts.
Immunohistochemistry:  Immunohistochemistry  (IHC)
staining was performed using primary antibodies (Table 2) for
human nuclei (HNu), human nestin, DCX, Tuj1, recoverin,
rhodopsin,  glial  fibrillary  acidic  protein  (GFAP),  human
synaptophysin, Ki67, and ionized calcium-binding adaptor
molecule-1 (Iba-I).
Eye sections demonstrating the presence of grafted cells
by CV (Figure 1H,I) were sequentially incubated with 0.1%
Triton X-100/PBS (PBS-T) at room temperature for 30 min,
followed by 1 h incubation in blocking solution (5% pre-
immune serum and 0.1% PBS-T) at room temperature, and
then incubated with primary antibodies diluted in blocking
solution at 4 °C overnight. HNu antibody was used to identify
grafted  human  cells  [18,21].  Ki67  antibody  was  used  to
examine  the  mitotic  activity  of  cells  [22].  Human  nestin
antibody was used to identify multipotential human neural
precursor  cells  [23].  Tuj1  antibody  was  used  to  identify
neuronal  cells.  DCX  antibody  was  used  as  a  marker  for
neuroblasts and young neurons [24]. Recoverin and rhodopsin
antibodies  were  used  as  PR  markers  [25].  Human
synaptophysin antibody was used to identify the presynaptic
part of human boutons established by maturing hESC-RPCs
[6]. GFAP antibody was used as a marker for activated Müller
glia cells [26]. Iba-1 was used to identify microglia cells
[27]. DAPI staining was used to identify nuclei of any cell
type.  Following  overnight  incubation  with  primary
antibodies, sections were washed three times with 0.1% PBS-
T  and  then  incubated  with  the  corresponding  secondary
antibodies (Alexa Fluor 594 goat antimouse, Alexa Fluor 488
goat antirabbit) at room temperature for 45 min. The slides
were washed three times with 0.1% PBS-T solution, incubated
with 4', 6-diamidino-2-phenylindole (DAPI) solution (1 μg/
ml) for 10 min, and then washed again with 0.1% PBS-T
solution. For negative controls, slides were treated similarly
except that primary antibodies were omitted. The specimens
were  mounted  with  ProLong  Gold  Antifade  medium
(Invitrogen) and examined using an Olympus (Center Valley,
PA) epifluorescent microscope IX51 with a Spot (Sterling
Heights, MI) CCD Camera RT3 and Leica (Buffalo Grove,
IL) SP2 confocal microscope. For high-resolution confocal
microscopy, z-series of images (with a z-step of 0.2 μm, 15–
20 optical sections) were collected using a 63x1.32 numerical
aperture oil immersion objective (Leica SP2). Consecutive
optical planes (z series) of selected fields were analyzed to
evaluate  distribution  and  co-localization  of  fluorescent
signals, with subsequent virtual resectioning at the x and y
axes.
Statistical analysis: Data on human RPC grafts at 3 weeks and
3 months were obtained from serial sections and evaluated by
the StatView program (Abacus Corporation, Baltimore, MD).
The  difference  in  Tuj1  and  recoverin  expression  between
TE03 and UC06 grafts was minimal at 3 weeks and 3 months.
Thus, results were grouped for two hESC lines for each time
point and plotted as a mean of the percentages of HNu –
positive ([HNu [+]) human cells carrying Tuj1 or recoverin in
grafts, with corresponding standard error of the mean (SEM).
Comparison of the statistical significance between expression
of  Tuj1  and  recoverin  in  the  subretinal  space  versus  the
epiretinal (vitreous) space was calculated with an unpaired
Student t test (with p<0.05 considered statistically significant)
after converting the percentage values to arc sin values [52].
TABLE 2. PRIMARY ANTIBODIES.
Target phenotypes Target proteins/ Epitopes Host Dilution Vendor
Primary antibodies
Neural stem cell and/or precursor Nestin (human, not rat/mouse-specific) Mouse 1:400 Millipore
Neuronal precursor Doublecortin (DCX) Guinea pig 1:3,000 Millipore
Neuron - early Type III b-Tubulin epitope J1 (Tuj1) Rabbit 1:1,000 Covance
Neuronal precursor Doublecortin-like kinase (DCAMKL1) Rabbit 1:50 Dr. Walsh, Harvard
Mitotic marker Ki67 antigen (NCL-Ki67p), Kiel University
-raised antibody # 67
Rabbit 1:1,000 Novocastra Labs
Human Nuclei -all Human nuclear protein epitope (HNu) Mouse 1:1,200 Millipore
Neuron -human Synaptophysin, human, not rat/ mouse –
specific(Syn)
Mouse 1:800 Millipore
Muller glia -activated GFAP Rabbit 1:700 DAKO
Photoreceptor Recoverin (Rec) Rabbit 1:1,000 Millipore
Rod photoreceptor Rhodopsin, Rho4D2 Mouse 1:100 Dr.Molday (UBC)
Microglia Ionized calcium binding adaptor
molecule-1 (Iba-1)
Rabbit 1:200 Waco Chemicals USA
Secondary antibodies
Alexa Flour 488 Goat anti-Rabbit Goat 1:400 Invitrogen
Alexa Flour 594 Goat anti-Mouse Rabbit 1:400 Invitrogen
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924Figure 1. Human embryonic stem cell 
retinal differentiation diagram, 
characterization of cells for ocular 
grafting, and graft identification by 
histological analysis. A: Human 
embryonic stem cells (hESCs) were 
neuralized by withdrawal of basic FGF 
(bFGF) and providing noggin 
morphogen at 100 ng/ml in adherent 
hESC cultures. Noggin was kept in 
adherent rosette cultures throughout the 
differentiation procedure. bFGF was 
applied at day 14 and was kept thereon 
until grafting. At day 28, rosettes were 
excised mechanically from the cultures 
and replated to start a passage-1 culture 
of pure neural rosettes; Wnt-inhibiting 
morphogens Dkk-1 and IGF-1 (10 ng/ml 
each) were added and were kept for 1 
week to direct the early neuroectoderm 
toward early retinal fate. From day 35 to 
day 50 (grafting), the late neural rosettes 
were kept in dense cultures in 
Neurobasal medium supplemented with 
1x B27/N2 and bFGF+FGF9 (10 ng/ml 
each) to bias early retinal cells toward a 
neural retina rather than an RPE cell fate. 
B: These are neuralized hESCs (neural 
rosettes), shown at day 28 after initiation 
of neural differentiation protocol (the 
scale bar represents 50 µm). C: These 
are early neurons differentiating from 
late neural rosettes harvested for cell 
transplantation on day 50 and replated at 
high density (the scale bar represents 50 
µm). D-F: These are cells replated 
immediately after transplantation at low 
density and analyzed the next day. The 
cells display neural (nestin) or early 
neuronal (Tuj1) immunophenotypes with 
only rare cells (less than 1%) displaying 
nestin [-] Tuj1 [-] immunophenotype (shown with a white arrow in [F]), (the scale bar represents 10 µm). G: This is quantitative 
RT PCR analysis of hESC-derived retinal progenitors prepared for transplantation at day 50 of retinal differentiation protocol;  -
ACTIN and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as the housekeeping genes for normalization. The 
analysis was done in technical triplicates, with one biologic replicate, therefore no error bars are shown. Expression level values 
for all genes at day 50 (grafting) are presented as the binary logarithm (log2) values (fold change) using comparative  Ct 
g2 [1]) represents no change in gene expression at day 50 (compared to that at day 0, in 
undifferentiated hESCs). Markers of pluripotency, NANOG, OCT3/4, and SOX2, are downregulated in human embryonic stem 
cell-derived retinal progenitor cells (hESC-RPCs) at day 50, while a forebrain progenitor marker FOXG1, several eye field 
markers (RX (RAX), PAX6, LHX2, SIX6), early neural retinal progenitor markers (CHX10, MASH1, MATH5, NEUROD1), 
photoreceptor marker recoverin (RCVRN), retinal ganglion cell (RGC) marker (BRN3B), and horizontal marker (PROX1) show 
upregulation. The retinal pigment epithelium-specific isoform of MITF shows only a slight upregulation, indicating that the cells 
were induced toward neural retina rather than an RPE fate. H: Characteristic large subretinal graft found at 3 weeks following 
cell transplantation, cresyl violet (CV) staining. Major retinal cell layers and RPE are indicated. The asterisk shows the likely 
needle track from injection, which has several separated RPE cells embedded into the graft cell mass but overall caused little 
damage to the RPE. The inset shows an overview of a mouse eye carrying such a graft (the scale bar represents 100 µm). I: 
Typical large subretinal graft surviving for 3 months after transplantation, CV staining. Cells left on top of the RGC layer during 
needle withdrawal formed epiretinal grafts (**), which were found frequently in sections, and showed no tumors but persisted in 
a less differentiated state. The right inset shows the overview of a mouse eye section carrying such a graft. The closed 
arrowheads show a graft spreading within the subretinal space. The inset on the left is a fluorescent image showing the spreading 
of grafted HNu [+] Tuj1 [+] hESC-RPCs in the subretinal space (open arrowheads) at 3 months (the scale bar represents 100 µm).
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Differentiation of human embryonic stem cells to retinal cells:
We used noggin in the absence of bFGF mitogen for 2 weeks
to  neuralize  hESCs,  as  described  [53]  (Figure  1A).  The
detailed  protocol  is  outlined  in  Methods,  in  vitro
differentiation section of this paper. At day 28, the plates with
differentiating hESC colonies were 95% confluent, and about
one-third  of  each  plate  area  consisted  of  neural  rosettes
(Figure 1B). These rosettes were isolated mechanically as
described [53] (briefly, excised with a fine fire-polished and
sealed  pulled  glass  pipette),  replated  on  gelatin/laminin-
coated plates, and induced to a rostral neural tube cell fate by
Wnt  blocking  morphogen  Dkk-1  and  IGF-1  for  1  week.
Following  retinal  induction,  the  cells  (hESC-RPCs)  were
cultured  with  FGF9  and  bFGF  until  transplantation.
Immediately after transplantation, the remaining cells were
replated and evaluated by immunocytochemistry (ICC) the
following day (Figure 1F).
We noted an efficient neuralization of hESCs by day 28
and downregulation of pluripotency markers and upregulation
of neural and retinal markers by IHC and/or qRT–PCR by day
50 of our differentiation protocol (Figure 1A). About half
(52.7%) of the cells were mitotically active as judged by Ki67
positivity (not shown). The majority (64.2%) were human
nestin - positive (human nestin [+]; Figure 1D,F), and 39.8%
were Tuj1 [+] (Figure 1E,F; averaged for both hESC lines).
No recoverin [+] or rhodopsin [+] cells were detected at this
stage by ICC. Less than 1% of cells were human nestin [-] and
Tuj1  [-].  Pluripotent  hESCs  immediately  before  the
differentiation protocol and hESC-RPCs at day 50 (grafting)
were  used  for  total  RNA  preparation  and  qRT–PCR.
Pluripotency  markers  NANOG,  OCT3/4,  and  SOX2  were
downregulated  at  day  50,  while  the  eye  field  and  NR
progenitor  markers,  such  as  RX,  SIX6,  PAX6,  CHX10,
NEUROD1, early PR marker recoverin, and pan-RGC marker
BRN3B, showed substantial upregulation. The RPE-specific
isoform of MITF showed only a slight upregulation (Figure
1G).
Survival  and  morphology  of  subretinal  grafts:  Serial  CV
staining of grafts at 3 weeks after transplantation showed
surviving  transplanted  cells  clustered  around  the
transplantation site (Figure 1H). At 3 months more cells were
found spreading within the subretinal space (Figure 1I, also
see Figure 2G). Successful subretinal grafts (Figure 1H,I)
were observed in about 25% of transplanted eyes (n=3–4
grafts/hESC line). Many surviving grafts (n=14 examined)
were detected in the epiretinal area. In subretinal grafts, there
was a distinct border between the graft and the outer nuclear
layer  (ONL)  separated  by  the  OLM  (Figure  2A,B,G,
arrowheads). However, in cases where the host retina had been
damaged during transplantation, we observed some HNu [+]
Tuj1 [+] cells, and by 3 months we also observed HNu [+]
recoverin [+] neurons integrating into the ONL (Figure 2F,J).
The survival of xenogenic human grafts was best when the
host  RPE/choroid  was  not  damaged,  as  evaluated  by  CV
staining (as in Figure 1H,I). Sections that displayed damage
to the RPE/choroid (Figure 3A-C, arrows) displayed few or
no surviving HNu [+] cells and strong GFAP activation [54]
and  microglial  cell  accumulation  [55]  in  and  around  the
grafted area.
Some  grafts  demonstrated  slower  cell  degradation
evident by the release of human nuclear proteins into the
subretinal space, weak nuclei HNu antibody staining, and
HNu [+] immunoreactivity outside the grafted cells. Such
grafts also had strong activation of GFAP around, but not
inside, the grafted area (Figure 4). Iba-1 immunoreactivity
was prominent in grafts that did not survive (Figure 5).
Neural- and retinal-specific markers in grafts: Grouped data
for both hESC lines showed a reduction of immature neuronal
marker Tuj1 in 3-month subretinal grafts (57.2% Tuj1 [+]
hESC-RPCs [n=6], Figure 2E-G) compared to that at 3 weeks
(75.7% Tuj1 [+] hESC-RPCs [n=7], Figure 2B, also see the
plotted graph in Figure 2D). Further maturation of subretinally
located hESC-RPCs was evident as only 1.3% hESC-RPCs
were recoverin [+] at 3 weeks (n=7; Figure 2C and Figure 6)
whereas at 3 months 67.5% were recoverin [+] (n=6; Figure
2I,J, also see the plotted graph in Figure 7H). Approximately
15% of grafted cells were mitotically active at 3 weeks (n=7),
but only a few HNu [+] cells were stained with proliferation
marker Ki67 by 3 months (less than 0.01%, data not shown).
No tumor formation was observed in grafts. Human-specific
synaptophysin [+] sparse human boutons resembling boutons
en passant were found both on Tuj1 [+] axons emanating from
the grafted HNu [+] cells (Figure 2K, inset) and on host PRs.
In a few grafts (at 3 months only), cells were positive for
rhodopsin (Figure 2L).
Differentiation and migration of cells in subretinal versus
epiretinal  grafts:  Substantial  differences  were  found  in
maturation  of  hESC-RPCs  in  subretinal  versus  epiretinal
grafts  (Figure  7).  Subretinal  grafts  demonstrated  a  little
decrease of Tuj1 immunostaining (from about 75.7%, [n=7]
at  3  weeks  to  57.2%  [n=6]  at  3  months).  However,  the
difference was not statistically significant at p<0.05 when
combined for both TE03 and UC06 cells. Three-week-old
epiretinal grafts had less than 8% of Tuj1 [+] cells. By 3
months, only about 1% of cells in the epiretinal grafts were
HNu [+] Tuj1 [+], and these were mostly in small clusters
(Figure 7A). However, cells from epiretinal but not subretinal
grafts were able to easily integrate into the host’s RGC and
INL layers even when host retina was not damaged (Figure
2H, Figure 7A,B,E). Cells from the subretinal grafts were
detected in the ONL (and rarely in the INL) only when the
host retina was damaged (Figure 2F and Figure 7C,D,F). IHC
with  recoverin  and  HNu  antibodies  demonstrated  a  sharp
increase in the number of HNu [+] Rec [+] cells in subretinal
grafts from about 1% at 3 weeks [n=7] to about 67.5% at 3
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926Figure 2. Limited retinal integration but substantial maturation of human embryonic stem cell-derived retinal progenitor cells in subretinal
grafts. Immunostaining for A; doublecortin (DCX) and human nuclei (HNu), B; neuronal class III β-tubulin (Tuj1 epitope) and HNu, and
C; Photoreceptor (PR) marker recoverin and HNu in subretinal grafts. The asterisks indicate the areas shown in insets. Note the border
(indicated with closed white arrowheads) demarcating the outer nuclear layer (ONL) and the grafts in A and B showing the location of the
outer limiting membrane (OLM). Subretinal grafts consisted of mostly early neuronal cells (~76%), as shown in D. D represents grouped data
for both human embryonic stem cell (hESC) lines. Error bars indicate the standard error of the mean (SEM), (the means did not differ
significantly between the two hESC lines by an unpaired Student’s t-test). The Tuj1 marker is still heavily present in subretinal grafts at 3
months (E-H); however, the cells fail to migrate into the host’s ONL and remain in the subretinal space (E, H) unless the neural retina (NR)
is damaged by injection (F). As in A and B, the host’s OLM in the 3-month grafts presents a barrier for subretinally grafted cells to migrate
into the host’s ONL (G, shown with closed white arrowheads), although many grafts spread over a large subretinal area (also in G). H: Cells
from the epiretinal grafts integrate into the host’s retinal ganglion cell (RGC) layer, inner plexiform layer, and inner nuclear layer (INL). I-
L: Mature immunophenotypes, such as recoverin (I, J), synaptophysin (K), and rhodopsin (L), are observed in these grafts. In I and J, subretinal
grafts predominantly display recoverin-positive (an early photoreceptor) immunophenotype (shown in z-sections, see insets in I and J). The
asterisks point to areas within the main images shown in these insets. In I and J we compare the integration of early hESC-derived
photoreceptors into the host ONL in intact, nondamaged retinas (I) versus that, where retinas were damaged by the injection needle (J).
Compare I, no integration of HNu [+] cells in the host’s ONL can be seen, versus J, where Rec (recoverin) [+], HNu [+] PRs are found
embedded into the host’s ONL (indicated with two asterisks). Also see the respective inset (** in J). In K note sparse human synaptic boutons
(shown with white arrows and enlarged in inset) stained with human-specific synaptic marker synaptophysin (Syn) found both on graft- (shown
in inset) and host-specific neurons. The asterisks point to areas within the main images shown in the insets. The main images in the panel are
confocal images. The insets show confocal z-stack analysis of selected areas done with virtual resectioning along the x and y planes. Scale
bars: 20 μm (A, B, E, F, I, J, L); 50 μm (C, G, H); 10 μm (K).
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927months [n=6] (combined for both TE03 and UC06). Cells in
the epiretinal grafts displayed a low presence of recoverin [+]
human cells at 3 weeks (less than 2%), and no such cells were
present by 3 months. Note the complete absence of HNu [+]
recoverin [+] cells in the RGC/INL and clusters of HNu [+]
recoverin [+] cells in the subretinal space (Figure 7E). qRT–
PCR  analysis  corroborates  this  data  and  shows  that  early
progenitor/PR  markers  (RCVRN  [recoverin],  MASH1  and
NEUROD1) are upregulated at the time of grafting. Evidently,
such cells could undergo further maturation in the subretinal
but not epiretinal niche.
DISCUSSION
Stem cell-mediated cell replacement therapy for retina has
advanced  rapidly  in  the  past  several  years  and  has  the
possibility of becoming a treatment method for some retinal
degeneration  (RD)  conditions  [35,36,56].  Apart  from
reproducibility of the data from different hESC lines, many
issues require further evaluation; these include OLM barrier
[23,26,57,58], immunorejection of graft by a host [27,59]
(excellent discussion in [60]), and the formation of glial scar
containing  extracellular  matrix  and  Müller  glia  endfeet,
preventing further cell integration [58,61]. In addition, the
host retinal niche and preservation of retinal architecture of
the recipient seem to contribute to the complexity of any
graft’s survival and functional integration [24].
We considered it important to investigate two separate
recurrent  questions  frequently  reported  in  retinal  cell
transplantation papers: the survival of the retinal grafts in a
non-immunocompatible  recipient  and  the  population  of
retinal layers with grafted hESC-RPCs. We approached this
by first selecting normal (non-RD) young adult mouse eyes
Figure 3. The example of grafts, which did not survive due to damage done to retinal pigment epithelium/choroid layers. A: This is a three-
week-old subretinal graft with a typical neural retinal bulge but no human nuclei –positive (HNu [+]) cells. “V” is the vitreous space. The
arrow points to the damage done to retinal pigment epithelium/choroid tissue (RPE/Ch), which likely causes the rupture of the blood-retinal
barrier and exposes the xenogenic graft to the host’s immune system. B is the enlarged area shown in A, where RPE/choroid tissue is damaged
(arrow). C: This is a three-week-old human embryonic stem cell-derived retinal progenitor cell graft with only few surviving HNu [+] cells
left (white arrowheads); the RPE/choroid tissue is also damaged (white arrow). Panels D-E show the immunohistochemistry data done on
retinal sections carrying the graft displayed in panel A. In panel D we demonstrate the accumulation of glial fibrillary acidic protein (GFAP),
an early indicator of retinal distress, in the host retina. In panel E we show that microglia/macrophage marker ionized calcium binding adaptor
molecule 1 (Iba-1) (known to be upregulated during the activation of these immune cells) is heavily present inside the graft and in the host
retina around the grafted area. The asterisk shows the area in the main image, enlarged in the inset. The inset depicts several Iba-1 - positive
cells in the host neural retina, with a typical microglial morphology. The scale bar used in panels C-E is 100 μm. F: This is a surviving 3-
week-old subretinal graft shown for comparison; note the GFAP activation in the host retina above the graft, which did not affect the survival
of such graft. The scale bar used in panel F is 50 μm. Abbreviations used in this legend are the following: ONL, outer nuclear layer; INL,
inner nuclear layer; RGC, retinal ganglion cell (layer).
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928as recipients of hESC-RPC grafts to avoid the influence of a
degenerating  and  rapidly  changing  neural  niche  on  the
survival  of  the  graft  [24,62-64].  Such  reports,  although
debated,  suggest  that  an  injured  or  degenerative  neural
environment might adversely affect the survival of human
stem  cell-derived  grafts.  We  also  chose  not  to  apply
immunosuppression,  as  retina  is  considered  an
immunoprivileged site due to the blood-retinal barrier (BRB).
In addition, survival of xenogenic human grafts in retina has
been reported [50]. To account for the expected differences in
graft survival, we correlated the survival of transplanted cells
with the overall integrity of the RPE/choroid tissue, which
comprises the BRB [65]. Lastly, we compared the dynamics
of cell integration into the host’s retina from the subretinal and
epiretinal  space  to  circumvent  the  OLM  barrier.  The
advantage  of  such  an  approach  is  that  in  any  given
transplantation  case  the  grafting  niche  remains  the  only
difference, which may be informative for data interpretation.
Overall,  we  find  that  both  hESC  lines  UC06  and  TE03
(cultured for 50+ passages) can differentiate to mature retinal
phenotypes  using  the  noggin/Dkk-1/IGF-1/bFGF/FGF9
protocol.  After  3  months  in  a  subretinal  environment,
transplanted cells demonstrated the ability to acquire mature
PR-specific  immunophenotypes  (e.g.,  recoverin  and
rhodopsin staining) and no tumorigenicity was detected in all
examined grafts. Importantly, we observed that the survival
of xenogenic grafts with no immunosuppression correlates
with the integrity of the RPE/choroid structure (BRB) but not
the NR. Whenever the histology showed no damage to the
RPE/choroid, the graft survived and thrived for up to 12 weeks
with no immunosuppression and no signs of deterioration. The
damage to the host’s NR alone and/or strong activation of
GFAP by reactive Müller glia of the host (Figure 2 and Figure
3) did not affect graft survival. In cases when the RPE/choroid
Figure 4. Glial fibrillary acidic protein (GFAP) activation in the host retina around the grafting site 3 weeks after transplantation. GFAP
activation (A) was found in all examined cases where the subretinal grafts were found, regardless of whether the grafts survived or not. In the
case shown, the release of human nuclei –positive (HNu [+]) immunoreactivity was found in the grafting site outside of the nuclei, indicating
the initial stage of graft destruction (B, C). Inset in C shows a low-power image of the same graft from which the main panel was derived.
Panel D displays the staining of nuclei of both human and mouse cells with 4', 6-diamidino-2-phenylindole (DAPI). The scale bar used in
panels A-D is 50 μm. The outer nuclear layer (ONL) around the grafting site was damaged by the needle. The asterisk indicates the area shown
in the inset. Abbreviations used in this legend are the following: INL, inner nuclear layer; RGC, retinal ganglion cell (layer).
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929showed signs of substantial damage by a blunt needle guided
by the nano-injector, xenogenic hESC-RPC grafts did not
survive, displayed lysed human cells, were filled with host’s
Iba-1  [+]  microglia,  and  were  GFAP  [+].  Therefore,  we
conclude that the xenogenic grafts may survive and thrive in
the subretinal space when the BRB is intact. Consequently,
systemic immunosuppression may not be necessary for graft
survival when nonautologous PR progenitors are transplanted
into retina.
Our results showed limited integration of subretinally
grafted hESC-RPCs into the host’s retina and only in cases
when the ONL had some structural damage. However, no
HNu [+] cells (except one case) were found in INL or RGC
layers, likely due to intact OLM present in the wild-type
retina, consistent with other reports [19,23,57]. In contrast,
integration of hESC-RPCs into the host INL and especially
the  RGC  layers  was  efficient  from  the  epiretinal  grafts,
irrespective of whether the retina had any structural damage.
Some HNu [+] cells were co-localized with host RGCs and
also expressed RGC marker Tuj1 [66]. qRT–PCR analysis of
cells  at  the  time  of  grafting  showed  that  hESC-RPCs
upregulated RGC markers (such as MATH5 and BRN3B) and
the horizontal neuronal marker (e.g., PROX1). Thus, hESCs
could potentially generate RGCs and horizontal cells.
Figure 5. Microglia accumulation in a subretinal graft with damaged retinal pigment epithelium/choroid. This is a typical staining pattern
(A, B) observed in grafts where a needle penetrated retinal pigment epithelium (RPE) and disrupted choroid (Chr) vasculature (solid white
arrows in B), leading to the rupture of the retinal–blood barrier and exposure of xenogenic (human) graft to the host’s immune system. By 3
weeks after subretinal transplantation, there are typically no surviving human neurons in such grafts, yet some human nuclei-positive
immunoreactivity occasionally may be found. Solid white arrowheads point to the accumulation of ionized calcium binding adaptor molecule
1 (Iba-1) staining where the grafted cells were placed. The area of the main image displayed in the inset in panel B is indicated with an asterisk
(*). The inset shows several Iba-1-positive cells with a morphology typical for activated microglia. The scale bar used in panel B is 50 μm.
Double asterisk (**) in panel B indicates the area, enlarged in panels C and D. This is the host photoreceptor layer with high microglial activity,
where human retinal progenitors were earlier grafted but did not survive. Microglial processes are shown with double white arrowheads. The
following abbreviations were used in these panels: ONL – outer nuclear layer, INL, inner nuclear layer, RGC- retinal ganglion cells, DAPI –
4', 6-diamidino-2-phenylindole.
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930A limited number of human synaptophysin [+] boutons
en  passant  could be  detected  in  the  INL  and  RGC  layer,
indicating initiation of synaptogenesis. Due to the lack of a
barrier for cell penetration from the epiretinal side, such grafts
may be used for long-term trophic support of degenerating
retina  [67],  including  the  trans-synaptic  transport  of
neurotrophins [68], as well as for potential RGC and INL cell-
replacement strategies. Although the migration of cells into
the  ONL  from  subretinal  grafts  was  clearly  impeded,  we
suggest that in RD conditions this migration could be helped
by a porous OLM [69] as well as guided by tropism of grafted
progenitor cells to the sites affected by degeneration [5,70]. It
is also possible that the maturation state of hESC-RPCs affects
integration  as  some  studies  have  reported  integration  of
postmitotic progenitors and even mature PRs into normal
retina  [35,71].  Although  immunosuppression  may  not  be
crucial for xenogenic graft survival, it may be beneficial for
retinal integration in a clinical setting when nonautologous
(i.e., stem cell-bank-derived) hESC-RPCs are transplanted
subretinally. For example, removal of glial barrier in GFAP−/
− and vimentin −/− mice provided a permissive environment for
retinal integration of transplanted neurons [31]. Such a glial
barrier, induced by the host, may be partially alleviated by
immunosuppression and chondroitinase ABC [61].
We also noted that the subretinal but not the epiretinal
niche can provide further cues for hESC-RPC maturation to
PRs, resulting in a sharp gain of mature PR marker recoverin,
a neuronal calcium-binding protein found almost exclusively
in PRs [16]. However, the epiretinal grafts demonstrated no
cell maturation and retained the original, mostly nestin [+]
immunophenotype.  This  is  consistent  with  a  previous
observation [49] indicating that paracrine morphogens in the
host retina and/or RPE can promote further maturation of
hESC-RPCs.
As the cell population at the time of grafting showed
almost 100% neuralization with noggin and over 67% of cells
in grafts were positive for PR marker recoverin by 3 months,
the overall efficiency of PR-fate specification from both hESC
lines appears to be comparable to that reported [16]. Only a
small number of cells neuralized by noggin may be expected
to remain non-neural after 4 weeks in culture [53]. Since only
neural  rosettes  were  collected  for  further  induction  with
Dkk-1 and IGF-1, the number of non-neural cells in such
cultures should be minimal by day 50 (grafting), thus reducing
tumorigenicity.  There  are  several  important  distinctions
resulting  in  faster  derivation  of  recoverin/rhodopsin
immunophenotypes in cultures reported earlier [16]. These
differences  potentially  originate  from  somewhat  longer
exposure to Dkk-1 and IGF-1, culturing on Matrigel rather
than  defined  gelatin/laminin  coating,  and  likely  different
culturing  densities,  which  may  profoundly  influence  the
dynamics of neuronal cell fate acquisition and maturation
[72-74]. We also chose to maintain both bFGF and FGF9 in
neural cultures, which earlier received anteriorizing Dkk-1
and  IGF-1  induction,  as  both  bFGF  [75]  and  FGF9  [76]
reportedly bias early retinal cells to an NR rather than an RPE
cell fate.
Figure  6.  Absence  of  rhodopsin  and
scarce  presence  of  recoverin-positive
human cells in grafts at 3 weeks after
transplantation.  There  were  no
rhodopsin-positive cells in neural grafts
at this time point, although rhodopsin
staining  was  present  in  the  outer
segments of the host retina as expected.
Only few recoverin-positive cells were
identified in subretinal grafts at this time
point.  The  abbreviations  used  in  this
figure were the following: RGC, retinal
ganglion cells; INL, inner nuclear layer;
ONL, outer nuclear layer. The scale bar
used in this figure represents 50 μm.
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931Figure 7. Differences in retinal integration and 
maturation of human embryonic stem cell-
derived retinal progenitor cells (hESC-RPCs) 
transplanted into subretinal and epiretinal space. 
Confocal images in panels A-F represent 3-
month grafts. The majority of cells in epiretinal 
grafts (except for some rare larger human nuclei 
 positive, Tuj1   positive (HNu [+] Tuj1 [+]) 
clusters (shown in panel A) or HNu [+] Tuj1 [+] 
(RGC) layer (**) or inner nucler layer (INL) (*) 
but not inner plexiform layer (panel B) do not 
display the Tuj1 marker. The scale bar in panel 
A represents 50 µm. B: Many HNu [+] cells, 
including HNu [+] Tuj1 [+] neurons, were found 
layer (**). White arrows point to HNu [+] Tuj1 
[+] neurons in the host RGC layer. Inset in B is 
a high-power z-stack confocal image of the INL 
area shown with an asterisk (*), which has 
several HNu [+] Tuj1 [+] neurons. The scale bar 
in panel B represents 50 µm. C: Migration of 
when the retinal architecture was damaged by 
injection. D: Z-stack confocal analysis of the 
area shown in C with an asterisk, demonstrating 
the HNu [+] Tuj1 [+] neuron integrated in the 
E: The difference in acquisition of 
photoreceptor marker recoverin by subretinal 
grafts versus epiretinal grafts at 3 months 
following grafting. While the human cells 
located in the subretinal grafts display 
predominantly recoverin-positive 
immunophenotype (recoverin [+]), the human 
cells in the epiretinal grafts remain recoverin-
negative (recoverin [-]) and slowly migrate into 
the RGC and INL layers. White arrows show the 
elongated human nuclei, typical for migrating 
cells. The scale bar in panel E represents 50 µm. 
F: Integration of recoverin [+] human cells from 
the host retina was damaged during injection. 
The scale bar in panel (F) represents 50 µm. G: 
Different dynamics of loss of immature 
neuronal marker Tuj-1 in subretinal and 
epiretinal grafts. In the subretinal grafts (black 
bars), the reduction of the number of HNu [+] 
Tuj1 [+] cells in grafts in time from ~76% (3 
week, n=7) down to ~57% (3 months, n=6; grouped for both hESC lines) is due to the maturation of cells to a recoverin [+] 
developmental state (shown in H). In the epiretinal grafts (gray bars), the majority of cells (more than 92% at 3 weeks and about 
99% by 3 months) are Tuj1 [-], with many cells being nestin - positive (not shown). Values represent the mean percentage of 
HNu [+] Tuj1 [+] cells in human grafts±standard error of the mean (SEM); **, p<0.005; ***, p<0.0005. The percentage of HNu 
[+] Tuj1 [+] cells in subretinal grafts was statistically higher compared to that in epiretinal grafts, both at 3 weeks and at 3 
months. There was a trend for reduction of the percentage of HNu [+] Tuj1 [+] cells in human grafts at 3 months, compared to 
that at 3 weeks, but the difference was not statistically significant. H: The dynamics of acquisition of the photoreceptor marker 
recoverin in subretinal and epiretinal grafts. There are no differences in the number of recoverin [+] human cells (less than 1% 
HNu [+] recoverin [+] cells) in subretinal and epiretinal grafts at 3 weeks following grafting. However, while cells in the 
epiretinal grafts continue to be recoverin [-] at 3 months following transplantation, cells in the subretinal grafts mature to a 
recoverin [+] immunophenotype (about 67.5%, n=6). Values represent the mean percentage of HNu [+] Rec (recoverin) [+] cells 
in human grafts±SEM; ***, p<0.0005.
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especially  interesting  as  it  is  unexplored  in  retinal
differentiation protocols. Fgf9 is expressed in the distal part
of the developing optic vesicle in the mouse that is destined
to become a NR and was reported to induce activation of
Ras by receptor tyrosine kinase in early optic neuroepithelium
[76]. Ectopic expression of Fgf9 in the proximal region of the
optic vesicle destined to become RPE promotes conversion of
the  RPE  cell  fate  to  an  NR  cell  fate  in  early  retinal
development by suppressing the expression of RPE marker
Mitf and induction of NR-specific markers Rx,Chx10, and
Atoh7 (Math5) [76]. As a result of such ectopic expression, a
duplicated NR has been produced. Notably, the original NR
and  duplicated  NR  differentiated  and  laminated
symmetrically but with a mirror-image polarity. The same
study  delineated  the  likely  downstream  target  of  FGF9
signaling, promoting the acquisition of the NR cell fate: the
RAS-mediated RAF-MEK-mitogen-activated protein kinase
pathway.  Specifically,  the  transient  expression  of  a
constitutively  active  human  Ras  oncogene  by  tyrosinase-
related  protein2  (TRP2)  promoter  in  mouse  transgenic
embryos also converted the developing RPE to a second NR.
Because the retinal development in both types of transgenic
mice was overall normal, it was concluded by Zhao et al.
[76] that FGF9 signaling was needed to define the boundary
between the retina and the RPE. Collectively, transient FGF9
signaling, likely through RAS signaling, was sufficient to
promote NR cell fate at the expense of RPE, which was one
of the goals of our differentiation protocol. Other factors, such
as ectopic Pax6 expression or null mutation of Chx10, are
known to shift the cell fate in the developing retina from RPE
to NR and vise versa, respectively. However, such signaling
requires genetic manipulations in hESCs compared to easy
delivery  of  FGF9  (and  bFGF)  morphogens  during  the
differentiation protocol.
FGF9 belongs to a different subfamily of FGF factors
compared  to  bFGF  (FGF2)  and  can  inhibit  the  canonical
Wnt  pathway  via  upregulation  of  Dkk-1,  a  canonical  Wnt
antagonist, and regulate the transcription of Hedgehog targets
patched homolog 1 (Ptch1) and glioma-associated zinc finger
1 (Gli1) independently of the Hedgehog ligand [77]. Both
effects may promote NR differentiation [16,78]. Additional
investigations are necessary to clearly delineate the role of
FGF9 in NR differentiation.
In summary, we show that (i) xenogenic human hESC-
RPC grafts from both hESC lines survive in the subretinal
space  without  immunosuppression  when  little  structural
damage occurs to the RPE/choroid; (ii) gradual maturation of
hESC-RPCs in subretinal but not epiretinal grafts occurs over
a period of 3 months, indicating that the subretinal but not the
epiretinal  (vitreous)  niche  provides  further  differentiation
cues for retinal cell fate maturation; (iii) substantial migration
and integration of hESC-RPCs into the RGC and INL layers
from epiretinal grafts occurs, even when the host retina lacked
signs  of  damage.  Our  data  provide  new  insights  into
differentiation  and  integration  of  grafted  cells  and  may
advance the protocols for cell therapies of retinal degenerative
diseases.
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